Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines

Next Previous
Trial Profile

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Facial wrinkles
  • Focus Registrational; Therapeutic Use
  • Acronyms REALISE1
  • Sponsors Revance Therapeutics

Most Recent Events

  • 08 Sep 2016 Status changed from active, no longer recruiting to completed.
  • 13 Jun 2016 According to a Revance Therapeutics media release, based on the disappointing results of this trial, the company has decided to disontinue the development of RT001 topical for crow's feet. Based on these results, they company has also decided not to pursue the current clinical development plan for RT001 in axillary hyperhidrosis.
  • 13 Jun 2016 Primary endpoint (The primary efficacy endpoints are composites based upon the Investigators Global Assessment of Lateral Canthal Lines (IGA-LCL) assessment and the Patient Severity Assessment (PSA) between baseline and 28 days after treatment.) has not been met, according to a Revance Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top